News & Media

Medicure Announces Private Placement

Medicure Inc. ("Medicure" or the "Company") (TSX: MPH) announces its plan to raise up to $3.0 million to improve its financial position through a non-brokered private placement of common shares (the "Offering") at a price of $0.05 per common share.

More

Ray of Hope for Cancer Patients

The technology, called the AutoLITT System, uses an MRI-guided laser probe, passed through a hole in the skull about the size of a dime, to deliver laser interstitial thermal therapy (LITT) to heat and coagulate the tumour from the inside.

More

Kane Biotech Announces Private Placement Offering

Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms (the “Company”), today announces a non-brokered private placement offering (the “Offering”) for gross proceeds of up

More

Scientists Learning To Target Bacteria Where They Live

In the arms race between humans and bacteria, the ability to form "biofilms" -- large aggregations of microbes embedded in a slimy matrix -- has been one of the weapons the organisms use to defeat the immune system, antibiotic drugs and other threats. But

More

MGI Pharma vet takes DiaMedica reins

Reggie Bowerman saw the doors close at MGI Pharma Inc.’s former headquarters late last year. Now, he’s aiming to open some new doors in biotech for a Canadian startup setting up shop in Minnesota.

More

Miraculins Announces Amendment to Private Placement Offering

Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on Novemb

More

LSAM Recognizes Leaders in the Life Science Sector

The Life Science Association of Manitoba (LSAM) awarded its annual Life Science Awards this week. Recognizing the leaders and innovators of the life science community, the awards highlight the great work being done in this growing and dynamic industry.

More

Medicure Launches New Clinical Program

Medicure Inc. (TSX: MPH) is pleased to announce initiation of a clinical program to investigate the efficacy and safety of Avastrem(TM) (pyridoxal 5'- phosphate) for the management of tardive dyskinesia. The Company will provide details of the planned tar

More